|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, the data presented in this work suggest that exogenous C1P may balance adipogenesis, and that targeting CerK may be a novel way for potential applications in the treatment of obesity or other inflammation-associated diseases.
|
30267661 |
2018 |
|
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
It can be concluded that CerK is a novel regulator of adipogenesis, an action that may have potential implications in the development of obesity, and that targeting this kinase may be beneficial for treatment of obesity-associated diseases.
|
28951635 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, our findings identify a functional role for Cerk in breast cancer recurrence and suggest the clinical utility of agents targeted against this prosurvival pathway.
|
25164007 |
2014 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, our findings identify a functional role for Cerk in breast cancer recurrence and suggest the clinical utility of agents targeted against this prosurvival pathway.
|
25164007 |
2014 |
|
Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)₂D₃ and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.
|
22579669 |
2012 |
|
Central neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)₂D₃ and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.
|
22579669 |
2012 |
|
Childhood Neuroblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)₂D₃ and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.
|
22579669 |
2012 |
|
Neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined CERK mRNA level during all-trans retinoic acid (ATRA)-induced differentiation of a human neuroblastoma cell line, SH-SY5Y.
|
19903244 |
2010 |
|
Central neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined CERK mRNA level during all-trans retinoic acid (ATRA)-induced differentiation of a human neuroblastoma cell line, SH-SY5Y.
|
19903244 |
2010 |
|
Childhood Neuroblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined CERK mRNA level during all-trans retinoic acid (ATRA)-induced differentiation of a human neuroblastoma cell line, SH-SY5Y.
|
19903244 |
2010 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.
|
19125296 |
2009 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.
|
19125296 |
2009 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to elucidate CerK/C1P functions in colitis, we examined the severity of dextran sodium sulfate (DSS)-induced colitis in wild-type (WT) and CerK deletion (CerK<sup>(-/-)</sup>) mice.
|
29709917 |
2018 |
|
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Quantitative PCR analyses demonstrated a significantly higher ceramide kinase and sphingosine kinase-2 expression in KS-ECFCs.
|
29345349 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, PDAC cells express the C1P converting enzyme ceramide kinase (CerK), secrete C1P-containing extracellular vesicles that mediate PCSC migration, and when co-injected with PCSC reduce animal survival in a PDAC peritoneal dissemination model.
|
30222969 |
2018 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
We find that Cerk is rapidly upregulated in tumor cells following HER2/neu downregulation or treatment with Adriamycin and that Cerk is required for tumor cell survival following HER2/neu downregulation.
|
25164007 |
2014 |
|
Recurrent tumor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We now report that ceramide kinase (Cerk) is required for mammary tumor recurrence following HER2/neu pathway inhibition and is spontaneously upregulated during tumor recurrence in multiple genetically engineered mouse models for breast cancer.
|
25164007 |
2014 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.
|
25164007 |
2014 |
|
SCHIZOPHRENIA 10
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study excludes genetic variations in the coding and putative promoter regions of KIAA0767 and KIAA1646 as causative factors for periodic catatonia.
|
16225677 |
2005 |